Highlights Rosetta Genomics Ltd.

Equities

ROSGQ

IL0011026494

Delayed OTC Markets Other stock markets 08:04:46 12/02/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	-.--%

2018	Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd..	CI
2018	Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd..	31/18/31	CI
Genoptix, Inc. and Rosetta Genomics Ltd. Enter into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide	13/18/13	CI
Genoptix, Inc. completed the acquisition of PDx Business of Rosetta Genomics Ltd..	02/18/02	CI
Genoptix, Inc. entered into a definitive agreement to acquire PDx Business of Rosetta Genomics Ltd. for $1 million.	27/18/27	CI
Genoptix, Inc. entered into a merger agreement to acquire Rosetta Genomics Ltd. for $8 million.	27/18/27	CI
Genoptix, Inc. cancelled the proposed acquisition of Rosetta Genomics Ltd..	22/18/22	CI
Genoptix, Inc. entered into a term sheet agreement to acquire Rosetta Genomics Ltd..	15/17/15	CI
Pragmin Prognosis cancelled the acquisition of CYNOGEN Inc. from Rosetta Genomics Ltd..	16/17/16	CI
Rosetta Genomics Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	10/17/10	CI
Pragmin Prognosis entered into a definitive agreement to acquire CYNOGEN Inc. from Rosetta Genomics Ltd. for $2.9 million.	08/17/08	CI
Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice	21/17/21	CI
Rosetta Genomics Ltd. Enters Collaboration with Meir Medical Center to Develop a microRNA Classifier Relating to Patients with Non Small Cell Lung Cancer Considered for Treatment with Immuno oncology Drugs	23/17/23	CI
Rosetta Genomics Receives Inquiries For PersonalizeDx Business	22/17/22	CI
Rosetta Genomics Mulls Acquisitions	08/17/08	CI
Rosetta Genomics Signs an Exclusive Distribution Agreement with Cytolog Laboratories	05/17/05	CI
Rosetta Genomics, Ltd. Announces Revenue Results for the First Quarter of 2017; Provides Revenue Guidance for the Year 2017	02/17/02	CI
Rosetta Genomics Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Provides Earnings Guidance for the Fiscal 2017	30/17/30	CI
Rosetta Genomics, Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	21/16/21	CI
Rosetta Genomics, Ltd. Enters into Research Collaboration with Sheba Medical Center to Develop microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients	21/16/21	CI
Rosetta Genomics Ltd. Enters into an Exclusive Distribution Agreement with Rhenium Ltd. for RosettaGX Reveal in Israel	29/16/29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Rosetta Genomics Ltd.

Equities

ROSGQ

IL0011026494

Highlights

Filters